{
     "PMID": "27936591",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20171025",
     "LR": "20180223",
     "IS": "1948-7193 (Electronic) 1948-7193 (Linking)",
     "VI": "8",
     "IP": "3",
     "DP": "2017 Mar 15",
     "TI": "Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.",
     "PG": "638-661",
     "LID": "10.1021/acschemneuro.6b00370 [doi]",
     "AB": "A novel systems therapeutics approach, involving simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylase (HDAC), has been validated as a potentially novel therapeutic strategy for the treatment of Alzheimer's disease (AD). First-in-class dual inhibitors bearing a sildenafil core have been very recently reported, and the lead molecule 7 has proven this strategy in AD animal models. Because scaffolds may play a critical role in primary activities and ADME-Tox profiling as well as on intellectual property, we have explored alternative scaffolds (vardenafil- and tadalafil-based cores) and evaluated their impact on critical parameters such as primary activities, permeability, toxicity, and in vivo (pharmacokinetics and functional response in hippocampus) to identify a potential alternative lead molecule bearing a different chemotype for in vivo testing.",
     "FAU": [
          "Sanchez-Arias, Juan A",
          "Rabal, Obdulia",
          "Cuadrado-Tejedor, Mar",
          "de Miguel, Irene",
          "Perez-Gonzalez, Marta",
          "Ugarte, Ana",
          "Saez, Elena",
          "Espelosin, Maria",
          "Ursua, Susana",
          "Haizhong, Tan",
          "Wei, Wu",
          "Musheng, Xu",
          "Garcia-Osta, Ana",
          "Oyarzabal, Julen"
     ],
     "AU": [
          "Sanchez-Arias JA",
          "Rabal O",
          "Cuadrado-Tejedor M",
          "de Miguel I",
          "Perez-Gonzalez M",
          "Ugarte A",
          "Saez E",
          "Espelosin M",
          "Ursua S",
          "Haizhong T",
          "Wei W",
          "Musheng X",
          "Garcia-Osta A",
          "Oyarzabal J"
     ],
     "AD": "Anatomy Department, School of Medicine, University of Navarra , Irunlarrea 1, E-31008 Pamplona, Spain. WuXi Apptec (Tianjin) Co. Ltd. , TEDA, No. 111 HuangHai Road, fourth Avenue, Tianjin 300456, PR China. WuXi Apptec (Tianjin) Co. Ltd. , TEDA, No. 111 HuangHai Road, fourth Avenue, Tianjin 300456, PR China. WuXi Apptec (Tianjin) Co. Ltd. , TEDA, No. 111 HuangHai Road, fourth Avenue, Tianjin 300456, PR China.",
     "AUID": [
          "ORCID: 0000-0003-1941-7255"
     ],
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article",
          "Research Support, Non-U.S. Gov't"
     ],
     "DEP": "20161227",
     "PL": "United States",
     "TA": "ACS Chem Neurosci",
     "JT": "ACS chemical neuroscience",
     "JID": "101525337",
     "RN": [
          "0 (Histone Deacetylase Inhibitors)",
          "0 (Phosphodiesterase 5 Inhibitors)",
          "8L70Q75FXE (Adenosine Triphosphate)",
          "EC 3.1.4.17 (3',5'-Cyclic-AMP Phosphodiesterases)",
          "EC 3.1.4.17 (PDE9A protein, human)",
          "EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5)",
          "H2D2X058MU (Cyclic GMP)"
     ],
     "SB": "IM",
     "MH": [
          "3',5'-Cyclic-AMP Phosphodiesterases/metabolism",
          "Adenosine Triphosphate/metabolism",
          "Alzheimer Disease/*drug therapy/pathology",
          "Animals",
          "Cell Line, Transformed",
          "Cyclic GMP/metabolism",
          "Cyclic Nucleotide Phosphodiesterases, Type 5/metabolism",
          "Histone Deacetylase Inhibitors/chemistry/pharmacology/*therapeutic use",
          "Humans",
          "Leukocytes, Mononuclear",
          "Mice",
          "Microsomes, Liver/drug effects",
          "Models, Molecular",
          "Neuroglia/drug effects",
          "Neurons/drug effects",
          "Phosphodiesterase 5 Inhibitors/chemistry/pharmacology/*therapeutic use"
     ],
     "OTO": [
          "NOTNLM"
     ],
     "OT": [
          "*Alzheimer's disease",
          "*HDACs",
          "*PDE5",
          "*dual inhibitor",
          "*tadalafil",
          "*vardenafil"
     ],
     "EDAT": "2016/12/13 06:00",
     "MHDA": "2017/10/27 06:00",
     "CRDT": [
          "2016/12/13 06:00"
     ],
     "PHST": [
          "2016/12/13 06:00 [pubmed]",
          "2017/10/27 06:00 [medline]",
          "2016/12/13 06:00 [entrez]"
     ],
     "AID": [
          "10.1021/acschemneuro.6b00370 [doi]"
     ],
     "PST": "ppublish",
     "SO": "ACS Chem Neurosci. 2017 Mar 15;8(3):638-661. doi: 10.1021/acschemneuro.6b00370. Epub 2016 Dec 27.",
     "term": "hippocampus"
}